Healthcare / BiotechnologyTokyo
$317.00
-9.00 (-2.76%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 22%
FCF escenarios
weak_data · normalized FCF $-2.9B · quality 62.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
15/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$42.8B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-45.3%
↓Gross Margin
-109.6%
↓Debt/Equity
0.53
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+4.9%
FCF CAGR
—
FCF margin
-3204.8%
FCF / Net income
1.50x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $104.0M · net income $-2.22B · FCF $-3.33B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $104.0M | $104.0M | $560.0M | $121.0M | $90.0M |
| Net Income | $-2.22B | $-2.22B | $-4.24B | $-3.82B | $-5.17B |
| EBITDA | $-1.65B | $-1.65B | $-2.17B | $-2.70B | $-4.44B |
| EPS | -26.60 | -26.60 | -47.86 | -56.22 | -90.67 |
| Gross Margin | -109.6% | -109.6% | 77.1% | 90.1% | 100.0% |
| Operating Margin | -3211.5% | -3211.5% | -507.5% | -2792.6% | -5754.4% |
| Net Margin | -2131.7% | -2131.7% | -756.3% | -3159.5% | -5743.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.53 | 0.53 | 1.29 | 1.18 | 1.63 |
| Current Ratio | 2.05 | 2.05 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-3.33B | $-3.33B | $-2.12B | $-2.85B | $-4.86B |
| Returns | |||||
| ROE | -45.3% | -45.3% | -205.3% | -99.1% | -118.0% |
| Valuation | |||||
| P/B | 6.98 | 6.98 | 7.59 | 2.91 | 4.14 |
| Growth & Yield | |||||
| Revenue Growth | -81.4% | -81.4% | 362.8% | 34.4% | — |
| EPS Growth | 44.4% | 44.4% | 14.9% | 38.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-9.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-47.86 → -26.60
Residual
-9.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.